AstraZeneca’s tozorakimab shows up to 34% fewer COPD exacerbations
A Phase III trial found tozorakimab reduced COPD exacerbations by up to 34% across eosinophil levels, with safety comparable to placebo. AstraZeneca links its respiratory & immunology portfolio to 2030 growth targets.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.